KIM
DMAA

Karpus Investment Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Karpus Investment Management’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.7M Sell
2,507,817
-22,700
-0.9% -$240K 0.77% 30
2026
Q1 		$26.5M Sell
2,530,517
-8,125
-0.3% -$84.8K 0.83% 26
2025
Q4 		$26.3M Sell
2,538,642
-9,025
-0.4% -$93.2K 0.81% 33
2025
Q3 		$26.2M Sell
2,547,667
-196,442
-7% -$2.02M 0.83% 35
2025
Q2 		$28M Buy
2,744,109
+420,075
+18% +$4.25M 0.9% 29
2025
Q1 		$23.3M Buy
+2,324,034
New +$23.2M 0.75% 36

Other funds holding DMAA

MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.69% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.5% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
RC
RLH Capital Great Neck, New York $209M AUM

Karpus Investment Management's DMAA Position: Q2 2026 in Review

Karpus Investment Management reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 0.9% in Q2 2026, selling an estimated $240K and leaving 2,507,817 shares worth $26.7M. The position accounts for 0.77% of the portfolio, ranked #30.

Karpus Investment Management first reported a position in DMAA in Q1 2025 and has held it in 6 quarters since. The position peaked at $28M in Q2 2025. 18 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • Karpus Investment Management held 2,507,817 shares of Drugs Made In America Acquisition Corp worth $26.7M as of Q2 2026.
  • Karpus Investment Management sold 22,700 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $240K.
  • Drugs Made In America Acquisition Corp made up 0.77% of Karpus Investment Management's portfolio in Q2 2026, its #30 holding.
  • Karpus Investment Management first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and has held it in 6 quarters since.
  • Karpus Investment Management's Drugs Made In America Acquisition Corp position peaked at $28M in Q2 2025.
  • 18 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Karpus Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.